Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
16.1 USD | -3.48% | -11.78% | +67.36% |
Apr. 10 | North American Morning Briefing : Traders Await -2- | DJ |
Apr. 09 | TD Cowen Upgrades MacroGenics to Buy From Hold | MT |
Summary
- On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.
- From a short-term investment perspective, the company presents a deteriorated fundamental configuration.
Strengths
- Growth progress expectations are rather promising. Indeed, sales are expected to rise sharply in the coming years.
- Analysts covering this company mostly recommend stock overweighting or purchase.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
- Over the past four months, analysts' average price target has been revised upwards significantly.
- Consensus analysts have strongly revised their opinion of the company over the past 12 months.
Weaknesses
- The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
- The company has insufficient levels of profitability.
- Based on current prices, the company has particularly high valuation levels.
- For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
- The company's sales previsions for the coming years have been revised downwards, which foreshadows another slowdown in business.
- For the past year, analysts have significantly revised downwards their profit estimates.
- For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.
- Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Biotechnology & Medical Research
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+67.36% | 1.04B | C+ | ||
-3.39% | 102B | B+ | ||
+2.61% | 96.09B | B+ | ||
-1.02% | 22.05B | B | ||
-18.14% | 20.81B | B+ | ||
-6.87% | 19.06B | A- | ||
-40.70% | 16.05B | A- | ||
-26.89% | 14.01B | B | ||
+1.12% | 13.38B | C+ | ||
+22.25% | 11.01B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- MGNX Stock
- Ratings MacroGenics, Inc.